Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3648866 | 0.95 | ALOX5 (0.58) | ALOX5AOC3PTGESLTB4RLTB4R2 | |
| SCHEMBL3647548 | 0.93 | ALOX5 (0.51) | ALOX5AOC3PTGESLTB4RLTB4R2 | |
| SCHEMBL5106882 | 0.91 | LTB4R (0.58) | ALOX5LTB4RLTB4R2 | |
| SCHEMBL6715335 | 0.87 | PTGES (0.60) | ALOX5AOC3PTGESMTNR1AMTNR1B | |
| SCHEMBL6715386 | 0.85 | NPC1 (0.61) | ALOX5AOC3PTGESCHRM1CHRM3 | |
| SCHEMBL5105041 | 0.84 | LTB4R (0.53) | ALOX5LTB4RLTB4R2 | |
| SCHEMBL6716281 | 0.84 | AOC3 (0.50) | ALOX5AOC3PTGESMTNR1AMTNR1B | |
| SCHEMBL8084814 | 0.82 | ALOX5 (0.58) | ALOX5LTB4RLTB4R2CHRM2CHRM1 | |
| SCHEMBL6715294 | 0.82 | PTGES (0.57) | ALOX5AOC3PTGESLPAR1LPAR5 | |
| SCHEMBL6713540 | 0.82 | PTGES (0.54) | ALOX5AOC3PTGESLPAR1LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2004-09-30 | — | — | US | disclosed |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6608203-B2 | Devoid of unwanted side effects | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2001-11-08 | — | — | US | disclosed |
| EP-1113007-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | PFIZER INC. (US) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | ALOX5 644/4885AOC3 3151/4885PTGES 181/4885 |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | ALOX5 644/4885AOC3 3151/4885PTGES 181/4885 |
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | ALOX5 644/4885AOC3 3151/4885PTGES 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.